linzagolix

Linzagolix is a selective, non-peptide, small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist. It is used for the symptomatic treatment of moderate to severe uterine fibroids in adult women of reproductive age and has also been studied for endometriosis. Linzagolix works by competitively binding to GnRH receptors in the pituitary gland, inhibiting endogenous GnRH signaling and thereby suppressing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to reduced production of estrogen and progesterone by the ovaries, making it effective in managing estrogen-dependent conditions such as uterine fibroids and endometriosis. The drug is orally bioavailable with a half-life of approximately 15 hours[1][4][6][7].

Brand names

Yselty

Other names

linzagolix choline